Analysts Shared Their Read on 2 Stocks: Deluxe Corporation (DLX), Syros Pharmaceuticals, Inc. (SYRS)

The opening price for Deluxe Corporation (NYSE:DLX) was $41.95 and the volume amounted to 371669 shares which compares with the average volume of 481560 shares. The company stock experienced a 2.5% move to arrive at $43.

Deluxe Corporation (DLX) Analyst Opinion

Deluxe Corporation is currently rated as outperform by 3 stock analysts, with the company still having around 5.52% shares outstanding that can be sold short legally. The value of their shares went down by -6.34% last month. Over the course of a year, the stock has grown by 11.86%. Financial analysts are becoming more bullish than ever, with the 2 analysts who cover the activities of DLX advising investors to buy. Experts on Wall Street have set a price target of $66 for the stock. The decision was arrived after looking at their 53.49% gain from current levels. At the moment, Deluxe Corporation (DLX) trading price is around -45.48% below its 52-week high.

Deluxe Corporation Earnings Surprise

Deluxe Corporation (DLX) was successful in overcoming the expected $1.28 as the stock recorded an earnings of $1.36 a piece during their last financial report presentation. Revenue, meanwhile, had a distance of 1.39% from the previous quarter, with the company recording $495 million in revenue.

Deluxe Corporation (NYSE:DLX) Intraday View

The shares of Deluxe Corporation (NYSE:DLX) have struggled and recovered 17.17% ever since it recorded its 52 week low. During the course of 5 days, the stock price volatility has remained at 3.6%, increasing the time frame to a month, the volatility recorded was 4.16%. The price of their shares has been successful in staying above its 20 days moving average, staying at a distance of 7.8% and while its 50 moving average is around -4.49%. A look at previous five trading sessionDLX stock had returned 9.95% and sank -27.47% when compared to its 200-day moving average that is $53.96. Deluxe Corporation (DLX) will look to overcome its -44.59% fall that it witnessed in the past one year.

As the normal trading session ended, the stock of Syros Pharmaceuticals, Inc. (NASDAQ:SYRS), fetched in a $0.16 spike to $6.56. The session began with the stock price at $6.41, hitting a high of $6.91 before down again. For the week, analysts seem to be okay with their bullish with the consensus call staying at 1.9. Syros Pharmaceuticals, Inc. gets 2 buy analyst recommendations while 1 recommend a hold and 0 rated it as a sell. The shares of the company tumbled -52.67% from its high $13.86, with their overall market value now roughly $209.72 million.

Syros Pharmaceuticals, Inc. (SYRS) Consensus Price Target

The mean recommendation of SYRS on Reuter’s scale dropped from 2 to 1.86 within 30 days. This figure implies that the majority of analysts rate it as a buy. The price target for Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) is now around $22.8 a share, implying the stock has what it takes to grow by 247.56%. The recent trading session also indicated the stock needs to add 403.05% more meet analysts’ high consensus price target.

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Intraday Trading

The current trading volume of the company was 257436 shares during the last session. That compares with the recent average volume of 196440 shares. By the end of the regular trading session, the price volatility over a 1-week span was 8.7 while month stood 10.66%. The stock price of SYRS dropped to $6.41 during the day and at a certain time in 12 months it traded as low as $5.39. It has made a 21.71% recovery since its 52-week low point and has returned 17.77% year-to-date.